T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy.

ABSTRACT:

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which pathogenic B cells drive persistent inflammation and joint damage. Although CD19-targeted CAR-T cell therapy enables effective B-cell depletion, conventional ex vivo manufacturing and viral vector-based genetic modification limit its scalability and clinical application. Strategies that allow efficient CAR-T cell generation directly in vivo may therefore provide a more practical approach to sustained immune modulation.

Methods

We developed FuNV_CAR, a T cell-targeted fusogenic nanovesicle system that delivers preformed αCD19 CAR proteins to T cells via membrane fusion. FuNV_CAR was characterized for size, composition, and fusion specificity. CAR-T cell generation, persistence, a

SUBMITTER: Liang S 

PROVIDER: S-EPMC12922314 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature